According to Dizhe Pharmaceutical's announcement, in the first three quarters of 2026, it achieved operating income of 4.770 billion yuan, an increase of 713.50%; net profit attributable to shareholders of listed companies was 3,639 billion yuan, turning a loss into a profit; deducting non-net profit of 3.612 billion yuan; and R&D investment of 593 million yuan, a year-on-year decrease of 7.91%. Quarterly revenue for the third quarter of 2026 was 4.247 billion yuan, up 1736.09% year on year; net profit to mother was 3.849 billion yuan. The increase in performance was mainly due to a global licensing agreement with AstraZeneca on Schwarzer®. The $600 million down payment confirmed revenue during the reporting period. The application for marketing of Schwarzer® for new indications has been accepted by the US FDA, and several research pipelines are progressing steadily.

According to Dizhe Pharmaceutical's announcement, in the first three quarters of 2026, it achieved operating income of 4.770 billion yuan, an increase of 713.50%; net profit attributable to shareholders of listed companies was 3,639 billion yuan, turning a loss into a profit; deducting non-net profit of 3.612 billion yuan; and R&D investment of 593 million yuan, a year-on-year decrease of 7.91%. Quarterly revenue for the third quarter of 2026 was 4.247 billion yuan, up 1736.09% year on year; net profit to mother was 3.849 billion yuan. The increase in performance was mainly due to a global licensing agreement with AstraZeneca on Schwarzer®. The $600 million down payment confirmed revenue during the reporting period. The application for marketing of Schwarzer® for new indications has been accepted by the US FDA, and several research pipelines are progressing steadily.